Advertisement
Canada markets open in 6 hours 59 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7297
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    83.02
    +0.17 (+0.21%)
     

  • Bitcoin CAD

    91,342.02
    +439.06 (+0.48%)
     

  • CMC Crypto 200

    1,402.86
    -11.90 (-0.84%)
     

  • GOLD FUTURES

    2,316.30
    -30.10 (-1.28%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • NASDAQ futures

    17,329.50
    -20.50 (-0.12%)
     

  • VOLATILITY

    16.94
    -1.77 (-9.46%)
     

  • FTSE

    8,023.87
    +128.02 (+1.62%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6854
    +0.0004 (+0.06%)
     

Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and Ampio Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / August 9, 2018 / While it wasn’t the numbers Inovio reported in its second quarter financial report, it was a positive update on its phase 3 Reveal 1 clinical study of VGX-3100 that had traders cheering. Shares closed up over 11%. Ampio Pharmaceuticals didn’t have such a good day, trailing back to penny stock land after an SEC filing revealed that the company’s phase 3 trial for Ampion doesn’t have enough data to support regulatory approval.

RDI Initiates Coverage on:

Inovio Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=INO

Ampio Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=AMPE

ADVERTISEMENT

Inovio Pharmaceuticals, Inc. shares closed up 11.44% on Wednesday with nearly 2.2 million shares traded. The clinical-stage biotech reported second quarter results after the market closed on Tuesday. Wall Street learned an update on the company's phase 3 Reveal 1 clinical study evaluating VGX-3100 in treating cervical dysplasia caused by the human papillomavirus (HPV). Inovio said that enrollment is on track in the study and stated that it has "opened a total of 70 sites across 16 countries and are actively recruiting for REVEAL 1, Inovio’s Phase 3 clinical trial for treating cervical dysplasia (CIN) caused by the human papillomavirus (HPV)." Inovio also said, "The company anticipates opening approximately 90 sites globally by the end of August 2018. Also commenced during the quarter a Phase 2 clinical trial in its third indication to evaluate the efficacy of VGX-3100 in approximately 24 patients, adult men and women, with HPV-related anal dysplasia. This expansion increases the overall commercial value potential of our lead product, VGX-3100." For the quarter, Inovio reported a quarterly loss of $0.08 per share versus the loss of $0.35 that analysts had expected. This also compares to loss of $0.13 per share a year ago.

Access RDI’s Inovio Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=INO

Ampio Pharmaceuticals, Inc. shares closed down 78.71% yesterday on almost 18.8 million shares traded. The clinical trial stage biopharmaceutical company announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. This wasn't however the reason why shares plunged into penny stock territory. The company revealed in a regulatory update in an SEC filing that its lead drug candidate Ampion, which is being developed as a treatment for severe osteoarthritis of the knee, appeared to report positive results in a phase 3 trial at the end of 2017. Unfortunately, the data collected isn't enough to support regulatory approval. The FDA does not consider Ampion for marketing approval because the recently completed phase 3 clinical trial was not "adequate and well controlled. "The FDA recommended that Ampio "perform an additional randomized trial with a concurrent control group."

Access RDI’s Ampio Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AMPE

Our Actionable Research on Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Ampio Pharmaceuticals, Inc. (NYSE: AMPE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com